Find a Program
Find a Lab
Message from the Chief
Patient Documentary
Rock musician Pat Spurgeon recounts his battle with kidney failure and treatment by UCSF transplant surgeon Sang-Mo Kang in a recent documentary.
Transplant Video Library
View videos of lectures pertaining to transplantation given by some of the world's top experts on the subject.
Make a Gift
A gift to the Department of Surgery helps us discover new treatments and cures.
A Study of Factors That Affect Long-Term Kidney Transplant Function
Official Title:
Study of Long-Term Deterioration of Kidney Allograft Function (DeKAF)Basic Trial Information
| Phase | Type | Age | Sponsor | Protocol IDs | Status |
|---|---|---|---|---|---|
| N/A | Observational | N/A and older | National Institute of Allergy and Infectious Diseases (NIAID) |
R01AI058013 R01-AI058013 NCT00270712 |
Recruiting |
Study Design:
Cohort, Other
Trial Summary
The causes of deterioration of transplanted kidney function are poorly understood. The
purpose of this study is to determine the disease processes that cause transplanted kidney
dysfunction and loss in patients who received a kidney either recently or over a year prior
to entering this study. This study will also identify specific characteristics in kidney
transplant recipients that predict whether a kidney transplant will be successful.
Eligibility
Inclusion Criteria for Prospective Cohort:
- Received a kidney transplant within 10 days prior to study entry, on or after
10-01-2005 - Recipient of kidney or simultaneous kidney/pancreas with no additional transplant at
the time of the kidney transplant
Inclusion Criteria for Retrospective Cohort:
- Received a kidney transplant before 10-01-2005
- Recipient of kidney or simultaneous kidney/pancreas with no additional transplant at
the time of the kidney transplant - Undergoes a clinically indicated kidney biopsy due to new onset deterioration of
function, defined as having an increase in serum creatinine - The creatinine level on or before 01-01-2006 must be 2 mg/dl or less OR the patient
must have developed new onset proteinuria, defined as having a protein/creatinine
ratio of 0.4 or more
Detailed Description
Over time, chronic kidney graft dysfunction progressively threatens the long-term survival
of a kidney graft. The disease processes behind graft dysfunction are unclear. However,
chronic kidney graft dysfunction is likely to be caused by certain definable factors. Such
factors may include collagens III and IV, transforming growth factor (TGF)-beta, T and B
cell surface markers, cell cycle proteins, fibronectin, and laminin. Determining what
disease processes and which specific factors are most responsible for kidney graft
dysfunction may help in designing future interventional trials for kidney transplant
patients. The purpose of this study is to determine whether clinical, laboratory, and
histologic studies at the time of initial graft dysfunction will clarify the processes and
factors that lead to deterioration and loss of a kidney graft. This is an observational
study that will enroll participants who have recently received kidney transplants
(prospective cohort) and participants who have had kidney transplants for a longer period of
time and are now experiencing kidney graft dysfunction (retrospective cohort).
The duration of this trial may differ between participants, depending on when deterioration
of kidney graft function occurs. Participants will be followed until graft loss or death.
There are no exclusive study visits associated with this study. Study data are gathered from
routine laboratory follow-up tests completed at the participant's local medical center and
from information obtained at the time of kidney biopsy. Participants may need to undergo a
kidney biopsy as clinically indicated. At the time of biopsy, participants will also undergo
urine and blood collection.
Important
Final eligibility is determined by the health professionals conducting the trial and the protocol approved by the Committee on Human Resources (CHR) at the University of California, San Francisco (UCSF). The Patient Consent Form for this trial is available upon request. For more information about this trial, please see the full posting at ClinicalTrials.gov.
For More Information
For questions about this trial:
Mehdi Tavakol, M.D.
Phone: (415) 476-0789
Fax: (415) 502-8326
Mehdi.Tavakol@ucsfmedctr.org